{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114205","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.025034+00:00","generated_at":"2026-06-22T09:36:37.232711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing","bullets":["Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.","Cash and equivalents $361.5M at Sep 30, 2022 ($438.7M Dec 31, 2021); runway into 2025.","R&D expenses $22.8M (up from $10.5M) driven by BT5528, BT8009, and platform costs.","Received $10M option fee from Genentech for expansion of immuno-oncology collaboration.","BT5528 showed 22% ORR in ovarian, 67% in urothelial; expansion enrollment on track for Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114205","json":"https://secwatch.observer/filing/0001104659-22-114205.json","markdown":"https://secwatch.observer/filing/0001104659-22-114205.md","text":"https://secwatch.observer/filing/0001104659-22-114205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/0001104659-22-114205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/tm2229573d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:36:37.232711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"847405dccbc33d6736e7622614df682f893c8480","claim":"BICYCLE THERAPEUTICS PLC reported the third quarter ended September 30, 2022 results: net income Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share, EPS $(0.96) basic and diluted net loss per share.","evidence_excerpt":"Bicycle Therapeutics plc (the \"Company\") issued a press release announcing financial results for the fiscal quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922114205/0001104659-22-114205-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share"},{"label":"EPS","value":"$(0.96) basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}